PARI Pharma GmbH

Kernkompetenzen

PARI Pharma is developing a portfolio of inhalable drugs to treat respiratory diseases such as cystic fibrosis, bronchiolitis obliterans, asthma, and COPD as well as rhinosinusitis. The company is focusing on improving the therapeutic efficiency of existing treatments by combining PARI Pharma?s proprietary eFlow Technology Nebulizer Systems with in-house formulation development and optimization know-how. Goal is to maximize treatment efficiency and simultaneously minimize the treatment time to ultimately improve patient compliance. Besides the company?s proprietary drug development programs, PARI Pharma partners with selected pharma and biotech companies to develop new and improved therapies based on the partner?s proprietary compounds and PARI Pharma?s eFlow Technology Nebulizer Systems.

TÜV, CE, 510(k), DIN EN ISO 13485-2007, Medizinprodukterichtlinie 93/42/EWG, Certificate of GMP compliance for a manufacturer

Schlüssel- / Teilbranchen

• Medizintechnik: Anaesthesie, Beatmung, Wiederbelebung

Zertifizierungen

• GMP
• ISO 13485

Zielmärkte

keine Angabe

Zielländer

keine Angabe

Kooperationsangebote

keine Angabe